Stock Screener App

Gratuito -

Installare

748.75

0.74% 5.405

Regeneron Pharmaceuticals Inc (REGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché REGN Giù? Forum Previsione

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

Connor Clark & Lunn Investment Management Ltd. Has $21.56 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

B. Metzler seel. Sohn & Co. Holding AG Buys New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

(REGN) On The My Stocks Page - Stock Traders Daily

Multiple Myeloma Market on Track for Major Expansion by 2034, According to DelveInsight | Janssen Pharma, Regeneron Pharma, Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron - Barchart

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Myopic Macular Degeneration Market Forecasted to Surge - openPR

Retireful LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Multiple Myeloma Market on Track for Major Expansion by 2034, - openPR

Breakthrough Therapy BT Designation Market Is Booming - openPR

Artery Stenosis Drug Market Insights Comprehensive Trends, - openPR

Retinal Biologics Market: Future Scope, Growth Potential, - openPR

Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Regeneron: The Biotech Stock To Buy Now (NASDAQ:REGN) - Seeking Alpha

Eczema Therapeutics Market 2024-2031 Revenues Will Increase - openPR

10 Best Genomics Stocks To Buy Right Now - Insider Monkey

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga

Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3 - Insider Monkey

Familial Hypercholesterolemia Market Forecasted to Surge - openPR

Quest Partners LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Macular Degeneration Treatment Market Is Expected To Reach - openPR

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

10 Biggest Biotechnology Companies - Investopedia

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria - Yahoo Finance

Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP - Law360

Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Benzinga

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc. - MarketBeat

Cutaneous Squamous Cell Carcinoma Market Geographical - openPR

2 Top Growth Stocks to Buy on the Dip - AOL

Swiss National Bank Acquires 2,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Seizert Capital Partners LLC - MarketBeat

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewswire Inc.

Mizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by CIBC Asset Management Inc - MarketBeat

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research - MarketBeat

Rep. Greg Landsman Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat

Citigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral Recommendation - MSN

Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint - MSN

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria - Pharmaceutical Technology

Simplify Asset Management Inc. Purchases 3,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Check Out What Whales Are Doing With REGN - Benzinga

Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research - MarketBeat

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga

Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S. - Seeking Alpha

ING Groep NV Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

FDA to review Sanofi, Regeneron’s Dupixent sBLA for CSU - Pharmaceutical Business Review

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup - MarketBeat

Regeneron, Sanofi Get New FDA Review of Dupixent for CSU - MarketWatch

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous - The Bakersfield Californian

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Regeneron stock touches 52-week low at $785.31 By Investing.com - Investing.com Nigeria

Regeneron stock touches 52-week low at $785.31 - Investing.com

Citigroup Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat

28 Analysts Have This To Say About Regeneron Pharmaceuticals - Benzinga

Victory Capital Management Inc. Sells 2,273 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Los Angeles Capital Management LLC Sells 773 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Citi initiated coverage on Regeneron Pharmaceuticals setting a price target of $895 - Investing.com

Regeneron Pharmaceuticals' SWOT analysis: stock faces biosimilar challenge, pipeline promise - Investing.com

Parametrica Management Ltd Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease - Yahoo Finance

MQS Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Boosted by Dillon & Associates Inc. - MarketBeat

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - The Manila Times

Aigen Investment Management LP Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Regeneron to Unveil Breakthrough Blood Cancer Data: 23 Studies at ASH 2024 | REGN Stock News - StockTitan

OVERSEA CHINESE BANKING Corp Ltd Has $1.39 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight - PR Newswire

VRTX

$448.22

0.34%

ARGX

$589.18

0.46%

ALNY

$250.40

0.58%

BNTX

$102.64

0.27%

BGNE

$196.58

0.88%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters